All posts by Janos Penzes

Pharmacological Therapies

Approach Appropriate population Description
(Selective Progesterone Receptor Modulator, SPRM)
EU Market only
Young or premenopausal women
  • Orally administered
  • Treats multifactorial symptoms of uterine fibroids such as bleeding, amenorrhea, pain and fibroids size
  • Rapid and sustained reduction in heavy bleeding
  • Continuous reduction of fibroid size
  • Repeated 3-months treatment courses that need to be separated by off-drug interval
GnRH1 agonists Preoperative therapy in young or premenopausal women
  • Temporary treatment (3 to 6 months), fibroid re-growth on cessation
  • Flare effect during the first month
  • Route of administration: Injections
  • Adverse effects including loss of bone mineral density and menopausal symptoms
Pharmacological therapies used for treatment of Heavy Menstrual Bleeding (including LNG-IUS2, COC3, Oral progestogen, NSAIDs4 and tranexamic acid) Young or premenopausal women
  • Focused mainly on bleeding and /or pain. Limited or no effect on fibroid size
  • LNG-IUS are contra-indicated in women with distorted uterus
1 GnRH: Gonadotrophin releasing hormone

2 LNG-IUS: Levonorgesteral-releasing intrauterine system
3 COC: Combined oral contraceptive pill
4 NSAID: Non-steroidal anti-inflammatory drug